Evidence Level
Glucosamine is one of the most extensively studied joint supplements. The large GAIT trial (Clegg et al., 2006, n=1,583) found glucosamine HCl alone did not outperform placebo for overall OA pain, but a subgroup with moderate-to-severe pain showed significant improvement with the glucosamine-chondroitin combination. In contrast, European trials using pharmaceutical-grade glucosamine sulfate (Rotta preparation) have consistently shown significant benefits. Reginster et al. (2001) and Pavelka et al. (2002) demonstrated 3-year structural benefits with glucosamine sulfate, showing reduced joint space narrowing. The discrepancy between US and European trials is largely attributed to differences in formulation (HCl vs. sulfate) and product quality. Current ESCEO guidelines recommend crystalline glucosamine sulfate as a first-step pharmacological treatment for knee OA.
Recent studies have further elucidated the effects of glucosamine. A systematic review/meta-analysis by Ruiz-Romero et al. (2025) found that chondroitin sulfate-glucosamine significantly improved maximum mouth opening but not pain reduction compared to tramadol in TMD treatment. Rabade et al. (2024) noted that glucosamine sulfate slowed joint space narrowing in knee osteoarthritis, while chondroitin sulfate reduced pain and improved function, though their combination showed no significant benefits. Meng et al. (2023) conducted a systematic review and meta-analysis of 8 RCTs (n=3793), finding that the glucosamine-chondroitin combination significantly improved WOMAC scores compared to placebo in knee osteoarthritis treatment.
Additionally, Zhou et al. (2025) demonstrated through Mendelian randomization combined with meta-analysis that glucosamine supplementation reduces the risk of type 2 diabetes. These findings underscore the potential benefits of glucosamine across various conditions, though further research is needed to confirm these effects in larger and more diverse populations.